These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 3913221

  • 1. [Combined immunosuppression (cyclosporin, azathioprine, methylprednisolone) in patients at immunological risk after kidney transplantation].
    Hillebrand G, Castro LA, Illner WD, Schleibner S, Land W, Gurland HJ.
    Z Urol Nephrol; 1985 Dec; 78(12):667-71. PubMed ID: 3913221
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Results, over a 3-year, period of a triple combination: cyclosporin, azathioprine, prednisolone in high-risk kidney transplants].
    Hiesse C, Rieu P, Neyrat N, Charpentier B, Benoit G, Bellamy J, Fries D.
    Nephrologie; 1987 Dec; 8(3):127-9. PubMed ID: 3309700
    [Abstract] [Full Text] [Related]

  • 4. Effective prevention of interstitial rejection crises in immunological high risk patients following renal transplantation: use of high doses of the new monoclonal antibody BMA 031.
    Dendorfer U, Hillebrand G, Kasper C, Smely S, Weschka M, Hammer C, Racenberg J, Gurland HJ, Land W.
    Transplant Proc; 1990 Aug; 22(4):1789-90. PubMed ID: 2389450
    [No Abstract] [Full Text] [Related]

  • 5. [Combined basic immunosuppression following kidney transplantation. Cyclosporin A in combination with azathioprine and methylprednisolone].
    Land W, Illner WD, Zink RA, Castro LA.
    MMW Munch Med Wochenschr; 1983 Apr 29; 125(17):361-3. PubMed ID: 6408461
    [No Abstract] [Full Text] [Related]

  • 6. Cyclosporine mono-drug therapy.
    Salaman J.
    Transplant Proc; 1988 Jun 29; 20(3 Suppl 3):117-20. PubMed ID: 3291223
    [Abstract] [Full Text] [Related]

  • 7. Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.
    Shabtai M, Ben-Haim M, Zemer D, Malinger-Saavedra P, Rosin D, Kuriansky J, Lustig S, Shabtai EL, Shapira Z, Ayalon A.
    Isr Med Assoc J; 2002 Nov 29; 4(11 Suppl):935-9. PubMed ID: 12455184
    [Abstract] [Full Text] [Related]

  • 8. Renal transplantation in children using cyclosporin A and azathioprine.
    Clark AG, Rigden SP, Welsh KI, Bewick M, Koffman G, Haycock GB, Chantler C.
    Transplant Proc; 1989 Feb 29; 21(1 Pt 2):1685-6. PubMed ID: 2652552
    [No Abstract] [Full Text] [Related]

  • 9. Effect of duration of MALG therapy in a quadruple immunosuppressive protocol.
    Stratta RJ, D'Alessandro AM, Armbrust MJ, Pirsch JD, Sollinger HW, Kalayoglu M, Belzer FO.
    Transplant Proc; 1989 Feb 29; 21(1 Pt 2):1726-8. PubMed ID: 2652564
    [No Abstract] [Full Text] [Related]

  • 10. Compensatory hypertrophy of renal grafts with triple drug therapy.
    Ishikawa I, Shikura N, Shinoda A, Fukuda Y, Tsugawa R, Suzuki K.
    Nihon Jinzo Gakkai Shi; 1990 Aug 29; 32(8):929-32. PubMed ID: 2250411
    [Abstract] [Full Text] [Related]

  • 11. Reduction of immunosuppressive therapy after renal transplantation: a randomized study.
    Heering P, Westhoff A, Ivens K, Kutkuhn B, Grabensee B.
    Transplant Proc; 1994 Oct 29; 26(5):2530-2. PubMed ID: 7940778
    [No Abstract] [Full Text] [Related]

  • 12. Renal allograft immunosuppression. VI. Triple drug therapy versus immunosuppressive double drug combinations: histopathological findings in renal allografts.
    Isoniemi H, Krogerus L, von Willebrand E, Taskinen E, Grönhagen-Riska C, Ahonen J, Häyry P.
    Transpl Int; 1991 Sep 29; 4(3):151-6. PubMed ID: 1958279
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
    Gheith OA, Bakr MA, Fouda MA, Shokeir AA, Bayoumy A, Sobh M, Ghoneim M.
    Iran J Kidney Dis; 2008 Jan 29; 2(1):34-9. PubMed ID: 19367007
    [Abstract] [Full Text] [Related]

  • 17. Immunosuppressive protocols at transplantation centers in Turkey.
    Haberal M, Demirağ A, Bilgin N, Arslan G, Büyükpamukçu N.
    Transplant Proc; 1995 Oct 29; 27(5):2776-7. PubMed ID: 7482911
    [No Abstract] [Full Text] [Related]

  • 18. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.
    Opelz G, Döhler B, Collaborative Transplant Study.
    Transplantation; 2009 Mar 27; 87(6):795-802. PubMed ID: 19300179
    [Abstract] [Full Text] [Related]

  • 19. Long-term outcome after switch from cyclosporine-based triple-drug immunosuppression to double therapy at three months.
    Aichberger C, Eberl T, Riedmann B, Pernthaler H, Ofner D, Königsrainer A, Margreiter R.
    Clin Transplant; 1996 Apr 27; 10(2):209-12. PubMed ID: 8664521
    [Abstract] [Full Text] [Related]

  • 20. Long-term graft survival after conversion from cyclosporin to azathioprine 1 year after renal transplantation. A prospective, randomized study from 1 to 6 years after transplantation.
    Pedersen EB, Hansen HE, Kornerup HJ, Madsen S, Sørensen AW.
    Nephrol Dial Transplant; 1993 Apr 27; 8(3):250-4. PubMed ID: 8385294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.